GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (NAS:GMAB) » Definitions » Price-to-Owner-Earnings

Genmab A/S (Genmab A/S) Price-to-Owner-Earnings : 22.88 (As of Apr. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab A/S Price-to-Owner-Earnings?

As of today (2024-04-25), Genmab A/S's share price is $27.46. Genmab A/S's Owner Earnings per Share (TTM) ended in Dec. 2023 was $1.20. It's Price-to-Owner-Earnings for today is 22.88.


The historical rank and industry rank for Genmab A/S's Price-to-Owner-Earnings or its related term are showing as below:

GMAB' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.61   Med: 76.85   Max: 727.6
Current: 23.55

During the past 13 years, the highest Price-to-Owner-Earnings of Genmab A/S was 727.60. The lowest was 22.61. And the median was 76.85.


GMAB's Price-to-Owner-Earnings is ranked better than
64.94% of 174 companies
in the Biotechnology industry
Industry Median: 32.115 vs GMAB: 23.55

As of today (2024-04-25), Genmab A/S's share price is $27.46. Genmab A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.95. Therefore, Genmab A/S's PE Ratio for today is 28.81.

As of today (2024-04-25), Genmab A/S's share price is $27.46. Genmab A/S's EPS without NRI for the trailing twelve months (TTM) ended in was $1.04. Therefore, Genmab A/S's PE Ratio without NRI for today is 26.48.

During the past 13 years, Genmab A/S's highest PE Ratio without NRI was 1024.49. The lowest was 22.82. And the median was 65.54.


Genmab A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Genmab A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Price-to-Owner-Earnings Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 124.06 29.25 86.00 57.27 25.89

Genmab A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 57.27 30.45 41.77 43.01 25.89

Competitive Comparison of Genmab A/S's Price-to-Owner-Earnings

For the Biotechnology subindustry, Genmab A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Price-to-Owner-Earnings falls into.



Genmab A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Genmab A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=27.46/1.20
=22.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genmab A/S  (NAS:GMAB) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Genmab A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus